Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Novartis
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
AstraZeneca
Ipsen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Emory University